Chemistry:Cleminorexton
From HandWiki
Cleminorexton (INN; former developmental code name ORX750) is an orexin OX2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia.[1][2][3][4][5] It is taken orally.[5] The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company.[1][2][4] As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 "ORX 750". AdisInsight. Springer Nature Switzerland AG. 11 November 2025. https://adisinsight.springer.com/drugs/800073116.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Cleminorexton with Synapse". Synapse. PatSnap. 3 April 2026. https://synapse.patsnap.com/drug/4f2eb47d2ac1408aa4366dc9feaa2558.
- ↑ "Understanding idiopathic hypersomnia: diagnosis, pathophysiology, and management". Current Opinion in Pulmonary Medicine 31 (6): 597–604. November 2025. doi:10.1097/MCP.0000000000001221. PMID 40990641.
- ↑ 4.0 4.1 "Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play". 31 March 2026. https://www.fiercebiotech.com/biotech/lilly-pays-63b-upfront-sleep-disorder-focused-centessa-latest-neuroscience-play.
- ↑ 5.0 5.1 "Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda". 31 March 2026. https://www.biospace.com/deals/lilly-wakes-up-sleep-market-with-6-3b-centessa-buy-to-challenge-takeda.
Template:Wakefulness-promoting agents
 |  |
